Cromos Pharma on the upcoming implementation of EU Clinical Trial Regulation
Cromos Pharma on the upcoming implementation of EU Clinical Trial Regulation The long-awaited European Union (EU) Clinical Trial Regulation (Regulation (EU) No 536/2014) (CTR) will come into effect in early 2022. The CTR is intended to improve the submission and review processes for clinical trials via a centralized portal. In recent weeks, the European Medicines Agency (EMA) has confirmed that the clinical trial EU Portal and Database, the
Cromos Pharma's US BDD on COVID's impact on clinical research and recover for clinical trials sector
Cromos Pharma’s US BDD on COVID’s impact on clinical research and recover for clinical trials sector It has been over a year and a half since the COVID-19 pandemic hit, causing the deaths of almost 4 million people worldwide[i]. It also precipitated multiple shutdowns of economies and societies around the globe. Many countries, including the US are now well into a recovery phase. As of July 2021, just over 3.25 billion
Cromos Pharma highlights Sarcoma Awareness Month
Cromos Pharma highlights Sarcoma Awareness Month This July, Cromos Pharma is highlighting Sarcoma Awareness Month. What are sarcomas? Sarcomas are rare malignant (cancer) tumors that start in the bones and soft tissues. The most common type of sarcoma is soft tissue sarcoma. Four out of five sarcomas occur in soft issues. Over half of these are found in the leg but

TO FIND OUT MORE

INQUIRY@CROMOSPHARMA.COM